Registered title, quoted from ClinicalTrials.gov
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06725524, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Participants diagnosed with CD20-positive B-cell non-Hodgkin lymphoma confirmed by histopathology and/or cell biology who have previously received 2 or more lines of therapy
Inclusion criterion 1
Those who have previously received targeted CD47 or signal regulatory protein α (SIRRP α) therapy.
Exclusion criterion 3
Subjects who had undergone major surgery within 4 weeks prior to initial dosing or expected to have major surgery during the study period;
Exclusion criterion 7
Eastern Cooperative Oncology Group (ECOG) physical state score: 0-2
Inclusion criterion 2
The absolute count of neutrophil (ANC) ≥1.0×109/L;
Inclusion criterion 6
Platelets ≥75×10\^9/L (if bone marrow invasion doesn't exist)/≥50.0×10\^9/L (if bone marrow invasion exists);
Inclusion criterion 7
Hemoglobin ≥90 g/L;
Inclusion criterion 8
Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min;
Inclusion criterion 9
Total bilirubin ≤1.5×ULN, alanine aminotransferase ≤2.5×ULN, aspartate aminotransferase ≤2.5×ULN; Subjects with liver lesion: TBIL≤3×ULN, ALT≤5×ULN, AST≤5×ULN;
Inclusion criterion 10
International Standardized ratio and activated partial thromboplastin time ≤1.5 × ULN;
Inclusion criterion 11
Participants must have at least one evaluable or measurable lesion according to Lugano 2014 criteria.
Inclusion criterion 3
HIV infection, active syphilis, hepatitis B surface antigen (HBsAg) positive and HBV-DNA higher than the lower limit or 1000 copies /ml(500 IU/ml), HCV antibody positive and HCV-RNA higher than the lower limit or 1000 copies /ml
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06725524, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Key Inclusion Criteria:
- Participants diagnosed with CD20-positive B-cell non-Hodgkin lymphoma confirmed by histopathology and/or cell biology who have previously received 2 or more lines of therapy
- Eastern Cooperative Oncology Group (ECOG) physical state score: 0-2
- Participants must have at least one evaluable or measurable lesion according to Lugano 2014 criteria.
- Expected survival of at least 3 months;
- Suitable organ and hematopoietic function:
- The absolute count of neutrophil (ANC) ≥1.0×109/L;
- Platelets ≥75×10\^9/L (if bone marrow invasion doesn't exist)/≥50.0×10\^9/L (if bone marrow invasion exists);
- Hemoglobin ≥90 g/L;
- Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min;
- Total bilirubin ≤1.5×ULN, alanine aminotransferase ≤2.5×ULN, aspartate aminotransferase ≤2.5×ULN; Subjects with liver lesion: TBIL≤3×ULN, ALT≤5×ULN, AST≤5×ULN;
- International Standardized ratio and activated partial thromboplastin time ≤1.5 × ULN;
Key Exclusion Criteria:
- Confirmed central nervous system (CNS) lymphoma.
- Subjects who have received allogeneic hematopoietic stem cell transplantation (HSCT) or other organ transplantation
- Those who have previously received targeted CD47 or signal regulatory protein α (SIRRP α) therapy.
- Previous or current hemolytic anemia, Evans syndrome, arteritis;
- Subjects with previous or current other malignant tumors;
- Previous or current history of active autoimmune diseases;
- Subjects who had undergone major surgery within 4 weeks prior to initial dosing or expected to have major surgery during the study period;
- HIV infection, active syphilis, hepatitis B surface antigen (HBsAg) positive and HBV-DNA higher than the lower limit or 1000 copies /ml(500 IU/ml), HCV antibody positive and HCV-RNA higher than the lower limit or 1000 copies /ml
Quoted from ClinicalTrials.gov, NCT06725524, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06725524, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.